Actively Recruiting
Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke
Led by Xuanwu Hospital, Beijing · Updated on 2025-03-25
200
Participants Needed
1
Research Sites
154 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to evaluate whether the combination of Probucol with statin therapy can reduce the risk of vascular events and improve atherosclerosis outcomes in adults with ischemic stroke and confirmed atherosclerosis. The main questions it aims to answer are: Does adding Probucol to statin therapy reduce plaque burden more effectively than statins alone? Does the combination therapy lead to fewer cardiovascular and cerebrovascular events compared to statins alone? Researchers will compare participants receiving standard statin therapy to those receiving statins combined with Probucol to assess differences in plaque burden and the occurrence of vascular events. Participants will: Choose either standard statin therapy (with possible addition of ezetimibe or PCSK9 inhibitors) or the same therapy combined with Probucol 0.5g twice daily. Attend regular follow-up visits for monitoring atherosclerosis features and cardiovascular health over a 3-year period. Undergo imaging studies to evaluate changes in atherosclerosis and blood tests to monitor lipid levels and other biomarkers.
CONDITIONS
Official Title
Efficacy of Probucol Combined with Statins Treatment for Ischemic Stroke
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18 years or older
- Diagnosed with ischemic stroke confirmed by cranial CT or MRI
- Stroke occurred within the last 30 days
- Evidence of atherosclerosis in at least one major artery (carotid, coronary, aorta, renal, or peripheral arteries) confirmed by imaging
- Signed informed consent
You will not qualify if you...
- Allergy to Probucol or statins
- Non-atherosclerotic arterial stenosis such as vasculitis, moyamoya disease, or arterial dissection
- Potential cardiac embolic sources like atrial fibrillation, artificial heart valves, endocarditis, or patent foramen ovale
- Known bleeding disorders or hemorrhagic diseases including thrombocytopenia, hemorrhagic stroke, or gastrointestinal bleeding
- Severe heart diseases such as myocardial infarction or myocarditis
- Liver or kidney dysfunction beyond specified limits
- Ventricular tachycardia, bradycardia, torsades de pointes, or syncope of cardiac origin
- Prolonged QT interval or conditions/medications causing QT prolongation
- Severe illness with life expectancy under one year or cognitive/psychological issues preventing cooperation
- Use of Probucol or non-allowed lipid-lowering drugs within 30 days before enrollment
- Pregnant, breastfeeding, or trying to conceive
- Participation in another clinical trial with investigational drugs/devices within 30 days
- Planned surgery or intervention requiring stopping study medication
- Any other condition preventing adherence to study protocol or follow-up as determined by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Xuanwu Hospital
Xicheng District, Beijing Municipality, China
Actively Recruiting
Research Team
X
Xin Ma, Doctor
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here